BOSTON, Dec. 21, 2011 /PRNewswire/ -- To help emerging and mid-size biopharmaceutical companies address an increasingly challenging regulatory and commercial environment, PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it is introducing a series of executive briefings with clinical operations and outsourcing leaders worldwide. During these forums, PAREXEL will discuss how a spectrum of proven operating practices and relationship models can significantly reduce timelines and costs and streamline protocols and programs.
Through these educational briefings, designed for emerging and mid-size biopharmaceutical companies, PAREXEL senior project leaders and teams will discuss customized solutions that can assist companies in achieving their short- and long-term development and commercialization milestones. The teams will address key issues that may impact critical areas for emerging and mid-sized biopharmaceutical companies, including:
"Deep collaboration with emerging and mid-size biopharmaceutical companies has been part of our DNA for nearly 30 years. We are committed to continuing to work with these clients to help them navigate the next stages of their businesses in the 'niche-buster' era, and in a challenging regulatory and commercial environment," said Mark A. Goldberg, M.D., Chief Operating Officer, PAREXEL. "Through a flexible and innovative approach, we create solutions that are the 'right fit' for every client. We're looking forward to bringing this executive series to biopharmaceutical companies to assist them in determining paths forward to realize tangible results."
Attendees to the executive briefings will learn about how the delivery of best-practice outsourcing models can create significant value. The teams will review case studies showing how various relationship models--ranging from transactional and functional service approaches to preferred provider solutions and full strategic partnering-- have brought benefits to emerging and mid-size biopharmaceutical companies.
Leveraging its worldwide resources and technology infrastructure, PAREXEL has conducted clinical development programs on a global scale for clients across a broad range of therapeutic areas. The Company's vast investigator network, experience with various patient groups, and capacity to support innovative approaches to drug development can accelerate emerging and mid-size companies' efforts to deliver new medical treatments to the patients who need them. PAREXEL is well positioned to combine leading eClinical solutions with proven clinical processes to deliver meaningful operational improvements. For more information about the range of capabilities PAREXEL brings together to assist companies of all sizes, visit: http://www.PAREXEL.com/services-and-capabilities/.
About PAREXEL InternationalPAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 67 locations throughout 52 countries around the world, and has approximately 10,850 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.
For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $4 million in the second quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.
Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 as filed with the SEC on November 9, 2011, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts: Jennifer Baird, Senior Director of Public RelationsKim Leadley/Gene CarozzaPAREXEL InternationalPAN CommunicationsTel: +781-434-4409Tel: + 617-502-4300Email: Jennifer.Baird@PAREXEL.comEmail: PAREXEL@pancomm.com
|SOURCE PAREXEL International Corporation|
Copyright©2010 PR Newswire.
All rights reserved